IL1-RAP, has been identified as a marker of interest in the context of CML treatments, activating NK cells and blocking tumour growth at the same time. Diaclone and Inserm teams have been able to develop a CAR-T therapy to specifically target this biomarker, which has demonstrated great promise during preclinical studies.
Discover our new IL1RAP clones:
|Anti-Human IL1RAP Azide Free||B-L43||Detail|
|Anti-Human IL1RAP Azide Free||B-R58||Detail|
|Anti-Human IL1RAP Unconjugated||B-L43||Detail|
|Anti-Human IL1RAP Unconjugated||B-R58||Detail|